CTIS2024-511626-30-00进行中(未招募)1 期
MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy - MEMENTO
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+(—)
- 性别
- All
入选标准
- •Surgical resectable (, Adult patients (age = 18 years)., ECOG performance status 0 or 1 (cf. Appendix A)., Adequate hematological, renal and hepatic functions defined as: oAbsolute Neutrophil Count = 1.5 x 109/L oplatelets = 100 x 109/L ohaemoglobin = 5.6 mmol ototal bilirubin = 1.5 x upper normal limit ocreatinine clearance (Cockroft) > 30 ml/min, Patients must be willing to undergo two endoscopies for investigational purposes., Written, voluntary informed consent, Patients must be accessible to follow up and management in the treatment center
排除标准
- •Patients diagnosed with diabetes mellitus type 1 or 2 receiving anti-diabetic drugs., Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery., Pulmonary fibrosis, active, non-infectious pneumonitis and/or severely impaired lung func-tion precluding major surgery and/or radiation., Serious underlying medical condition which would impair the ability of the patient to re-ceive the planned treatment, including prior allergic reactions to drugs containing Cremo-phor, such as teniposide or cyclosporine., Dementia or altered mental status that would prohibit the understanding and giving of in-formed consent, Patients prescribed metformin or another anti-diabetic drug for any reason., Patients allergic or intolerant to metformin., Previous systemic therapy or radiotherapy on the oesophagus., Severe renal impairment (CLcr = 30 ml/min)., Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer, Previous systemic therapy for other forms of cancer within the last six months., Patients with prior allogeneic stem cell or solid organ transplantation, Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
研究者
相似试验
招募中
2 期
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant ChemoradiotherapyOesophageal AdenocarcinomaTumor MicroenvironmentNCT06687876Amsterdam UMC, location VUmc14
招募中
2 期
Therapeutic effect of metformin in rectal cancerRectal cancer.Malignant neoplasm of rectumIRCT20190726044335N1Shiraz University of Medical Sciences90
尚未招募
Unknown
Benefit of metformin for weight control and related parameters in obese patients of schizophreniaCTRI/2023/09/057609Government Medical College and Hospital Chandigarh
尚未招募
4 期
A study to evaluate the role of metformin in preventing the incidence and complications of superimposed pre-eclampsia in chronic hypertensive patientsCTRI/2024/01/061712Thanjavur medical college
招募中
3 期
Evaluation of the effectiveness of metformin in WOMAC index of overweight knee osteoarthritis patientsOsteoarthritis.Osteoarthritis of kneeIRCT20200522047538N2Mashhad University of Medical Sciences88
